← All companies
Arpeggio Bio
ActiveArpeggio Bio develops drugs targeting transcription factors using AI…
Summer 2019Founded 201820 peopleBoulder, CO, USA
About
Arpeggio Bio is a pioneering pharmaceutical company that develops drugs targeting transcription factors using AI and high-throughput RNA-sequencing. With $20M in venture funding, we've targeted "undruggable" proteins like NRF2, TEAD, and GPX4 where our lead program is rapidly progressing towards a DC for the treatment of IO-resistant melanoma. With partnerships with J&J and FORMA, we've validated our platform in rare disease and inflammation with a significant Phase I success.
Founders · 1
Joey AzofeifaFounder
Formerly “Arpeggio Biosciences”
Related startups
GEn1E LifesciencesSummer 2019
AI platform accelerating therapies for rare & inflammatory diseases.
Active
Asher BioSummer 2019
We build better immunotherapies
Active
